Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (10)

2024

  1. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  2. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

2021

  1. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449

  2. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2019

  1. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)

    Clinical and Translational Oncology

  2. Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))

    European Urology

2018

  1. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

    European Urology, Vol. 73, Núm. 3, pp. 462-468

  2. SEOM clinical guideline for treatment of kidney cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97